Key result
High-sensitivity cardiac troponin fails to reduce 1-year MI or cardiovascular death in type 1 MI.
Why the study?
The clinical implications of implementing high-sensitivity cardiac troponin testing and the Universal Definition of Myocardial Infarction recommendations were not well understood.
Does the implementation of a high-sensitivity cardiac troponin I assay and the Universal Definition of Myocardial Infarction improve the composite outcome of myocardial infarction or cardiovascular death in patients with suspected acute coronary syndrome?
RCT (n=48,282)
Open-label
stepped-wedge cluster randomized
Yes
Does the implementation of a high-sensitivity cardiac troponin I assay and the Universal Definition of Myocardial Infarction improve the composite outcome of myocardial infarction or cardiovascular death in patients with suspected acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Implementing high-sensitivity cardiac troponin testing increases the detection of myocardial injury and type 2 MI but does not improve 1-year clinical outcomes, highlighting a gap in evidence-based treatments for these newly identified high-risk patients.
BACKGROUND: The introduction of more sensitive cardiac troponin assays has led to increased recognition of myocardial injury in acute illnesses other than acute coronary syndrome. The Universal Definition of Myocardial Infarction recommends high-sensitivity cardiac troponin testing and classification of patients with myocardial injury based on pathogenesis, but the clinical implications of implementing this guideline are not well understood. METHODS: In a stepped-wedge cluster randomized, controlled trial, we implemented a high-sensitivity cardiac troponin assay and the recommendations of the Universal Definition in 48 282 consecutive patients with suspected acute coronary syndrome. In a prespecified secondary analysis, we compared the primary outcome of myocardial infarction or cardiovascular death and secondary outcome of noncardiovascular death at 1 year across diagnostic categories. RESULTS: Implementation increased the diagnosis of type 1 myocardial infarction by 11% (510/4471), type 2 myocardial infarction by 22% (205/916), and acute and chronic myocardial injury by 36% (443/1233) and 43% (389/898), respectively. Compared with those without myocardial injury, the rate of the primary outcome was highest in those with type 1 myocardial infarction (cause-specific hazard ratio [HR] 5.64 [95% CI, 5.12-6.22]), but was similar across diagnostic categories, whereas noncardiovascular deaths were highest in those with acute myocardial injury (cause specific HR 2.65 [95% CI, 2.33-3.01]). Despite modest increases in antiplatelet therapy and coronary revascularization after implementation in patients with type 1 myocardial infarction, the primary outcome was unchanged (cause specific HR 1.00 [95% CI, 0.82-1.21]). Increased recognition of type 2 myocardial infarction and myocardial injury did not lead to changes in investigation, treatment or outcomes. CONCLUSIONS: Implementation of high-sensitivity cardiac troponin assays and the recommendations of the Universal Definition of Myocardial Infarction identified patients at high-risk of cardiovascular and noncardiovascular events but was not associated with consistent increases in treatment or improved outcomes. Trials of secondary prevention are urgently required to determine whether this risk is modifiable in patients without type 1 myocardial infarction. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov. Unique identifier: NCT01852123.
No takes yet. Share an insight, caveat, or question.
Chapman et al. (2019) conducted an RCT in Suspected acute coronary syndrome (n=48,282). Implementation of high-sensitivity cardiac troponin I assay and Universal Definition of Myocardial Infarction recommendations vs. Contemporary troponin assay and existing diagnostic threshold was evaluated on Myocardial infarction (type 1 or type 4b) or cardiovascular death at 1 year (HR 1.00, 95% CI 0.82-1.21). Implementation of high-sensitivity cardiac troponin assays did not reduce the primary outcome of myocardial infarction or cardiovascular death at 1 year in patients with type 1 myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: